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1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Familial adenomatous polyposis (FAP), adenomatous polyposis coli
(APC), familial polyposis coli (FPC), attenuated adenomatous polyposis
coli (AAPC); phenotypic variants: Gardner syndrome, Turcot syndrome.
1.2 OMIM# of the disease
175100.
1.3 Name of the analysed genes or DNA/chromosome segments
APC (5q22).
1.4 OMIM# of the gene(s)
611731.
1.5 Mutational spectrum
• Reference sequences for variant description: LRG_130;
NG_008481.4; NM_000038.5; NC_000005.10.
• Mutation detection rate: 80–93% in classical FAP.1,2
• De novo events: 10–40%.1,3,4
• Broad spectrum of point mutations, 490% are truncating
(nonsense, del/ins, splice sites).2
• Mutational hot spots: c.3927_3931delAAAGA;p.(Glu1309Aspfs*4)
(11%), c.3183_3187delACAAA; p.(Gln1062*) (7%), c.637C4T;p.
(Arg213*) (3%), c.3202_3205delTCAA;p.(Ser1068Glyfs*57) (2%).
• The vast majority of mutations is located in the 5ʹ half of the gene,
mutations 3ʹ to codon 1700 are rare (1%).
• Genomic rearrangements: large deletions o10–15% in classical
FAP; large duplications are very rare.5,6
• In APC/MUTYH mutation-negative families, deep intronic muta-
tions not covered by routine methods have been identified in up to
8% of unselected and up to 30% of familial cases.7
• Post-zygotic mosaicism in 10–15% of de novo events.8
• For the mutational spectrum, see locus-specific databases:
http://databases.lovd.nl/shared/genes/APC; www.umd.be/APC/, and
www.hgmd.cf.ac.uk/ac/. Novel mutations are still being reported.
• For variants with no functional effect (‘polymorphisms’), see NCBI




• All patients with the clinical diagnosis of an attenuated or classical
colorectal adenomatous polyposis (at least 10 synchronous adeno-
matous polyps).9
• In pedigrees consistent with an autosomal recessive mode of
inheritance, screening for MUTYH mutations should be performed
preferably before APC screening.
• In case of few colorectal adenomas diagnosed at a young age, tumour
screening for microsatellite instability and immunohistochemical
staining should be considered (see 3.1, differential diagnoses).
• A careful clinical examination including histology is a prerequisite
for performing cost-effective mutation analysis.
(2) Germline mutation analysis:
• Direct sequencing of all 15 coding exons.10
• In some centres, screening of exons 3 to 15J (codon 1700) in all
patients and exons 1, 2, 15J-W (codons 1700-ter) in case of extra-
digestive manifestation only.
• In some centres, pre-screening of the gene by protein truncation
test of exon 15 (genomic level) or of the whole gene (RNA level)
and/or by DHPLC, SSCP, CSGE.
• Screening of the whole gene including promoter region for large
genomic anomalies (deletions, duplications) by MLPA or QMPSF.
• Linkage analysis and functional tests for interpretation of unclassi-
fied APC variants.
(3) High-throughput techniques/massive parallele sequencing
• Sequencing of the coding regions or the whole gene by next
generation sequencing (NGS) technologies.10
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• This is usually done in the context of commercially available or
customized gene panels including a number of genes related to the
phenotype and its differential diagnoses. These panels vary by
methods used and genes included (see, for example, NGS panel
database; www.eurogentest.org/index.php?id= 668).
• APC germline mutations (point mutations or large deletions/
duplications) are also identified as incidental findings in the context
of large-scale screening approaches (exome or genome sequencing,
chromosome analysis, (array)-comparative genomic hybridization),
which are performed in individuals with varying non-polyposis
phenotypes or population-based healthy controls both in a diag-
nostic or research setting.
1.7 Analytical validation
As with other molecular genetic diagnostic tests, analytical results can
be validated using standard procedures of internal and external quality
assessment (EQA). These may include:
• Internal validation through analysis of known mutations (positive
controls).
• Direct sequencing of both DNA strands (bidirectional sequencing).
• Validation of NGS results by Sanger sequencing (if the read depth/
coverage or other NGS quality parameters are below defined thresholds).
• In case of assumed mosaicism confirmation of results with a second
method, using different primers and additional tissues.
• Confirmation of mutation in an independent biological sample of
the index case or an affected relative.
• In some cases (for example, single-exon deletions detected by
MLPA), the results of semiquantitative methods should be
confirmed by an independent technique (long-range PCR, RNA
analysis, different MLPA kit).
• External validation through exchange of DNA control samples with
other diagnostic institutions and participation in EQA schemes
(for example, www.emqn.org).
1.8 Estimated frequency of the disease (incidence at birth (‘birth
prevalence’) or population prevalence). If known to be variable
between ethnic groups, please report)
• Prevalence at birth: 0%
• Prevalence in general population: 2.3–3.2 per 100 0003,11
• Incidence: about 1:8 000–10 0003,11
• Prevalence in colorectal cancer patients: around 0.07%12
1.9 Diagnostic setting
Yes No
A. (Differential) diagnostics ⊠ □
B. Predictive testing ⊠ □
C. Risk assessment in relatives ⊠ □
D. Prenatal ⊠ □
Comment:
Prenatal diagnosis and preimplantation genetic diagnosis (PGD) are
rarely requested. An explanation might be that FAP is a relatively late-
manifesting and treatable disease. Another reason might be that some
FAP patients at child-bearing age are not informed about reproductive
options. In general, prenatal diagnosis and PGD should be performed
according to each countries' law, and only after appropriate, non-
directive genetic counselling.13
2. TEST CHARACTERISTICS















(proportion of positive tests if the genotype is present)
• Almost 100% (by direct sequencing of all coding exons and
deletion/duplication screening by methods such as MLPA.
• Can be distinctly less in mosaic cases, depending on degree of
mosaic and analysed tissue. In these cases, pre-screening methods
appear to be more sensitive than direct sequencing.8
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
Almost 100%.
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity dependent on variable factors such as age or
family history. In such cases, a general statement should be given, even
if a quantification can only be made case by case.
• Dependent on colorectal phenotype (number of adenomas), age,
and family history.2
• Mutations deep within introns or in regulatory elements are missed
with current standard methods,7 and the causal relevance of some
missense or intronic mutations is unclear, so far (variants of
uncertain clinical significance, VUS).
• Classic FAP: about 80–90%.1,2
• AFAP: about 20–30%.
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as
age or family history. In such cases, a general statement should be
given, even if a quantification can only be made case by case.
• Almost 100% (except for variants of uncertain clinical significance).
2.5 Positive clinical predictive value
(life-time risk to develop the disease if the test is positive)
• Penetrance in proven mutation carriers is almost complete. Due to
the high clinical variability, clinically mildly affected persons may
not be diagnosed or will be deceased for other reasons during
presymptomatic (sub-clinical) stage of the disease.
2.6 Negative clinical predictive value
(probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected
person. Allelic and locus heterogeneity may need to be considered.
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Index case in that family had been tested and a pathogenic germline
mutation was identified:
• Almost 100%.
Index case in that family had not been tested:
• As the mutation-detection rates in APC and MUTYH strongly
depend on the colorectal phenotype (mild versus more florid forms
of polyposis) and the family history (dominant vs. recessive pedigree
pattern), and – particularly in attenuated courses of adenomatous
polyposis – more and still unknown genes may be involved (locus
heterogeneity), no exact figures can be given.
• To test people at risk without having identified the underlying
germline mutations in a clearly affected index patient of the family
is in general not a meaningful approach and should therefore be
avoided, since persons at risk who are tested negative may still have
a substantial risk and cannot be released from surveillance.
• If no index patient is available in a family, mutation screening of risk
persons might be performed with the intention to identify the
familial mutation, which subsequently can be used for predictive
testing of other family members at risk. However, to date, no
guidelines or state-of-the art recommendations for this scenario exist.
3. CLINICAL UTILITY
3.1 (Differential) diagnosis: the tested person is clinically affected
(To be answered if in 1.9 ‘A’ was marked)
Clinical diagnostic criteria.
• According to polyp number and age at onset, the phenotype is
usually classified as classical (typical) FAP or attenuted FAP
(AFAP).14,15 However, it should kept in mind that the formation
of colorectal adenomas is a biological continuum without any
clearly delineated features. In particular, AFAP is not well defined as
a disease entity. Widely used clinical criteria are the following:
• Classical FAP: more than 100 colorectal adenomas; early onset
(polyp formation during second decade of life, gastrointestinal
symptoms during third decade of life).9
• AFAP: a milder course of the colorectal disease with a delay in onset
of adenomatous polyposis and colorectal cancer of 10–25 years
compared with classical FAP;o100 colorectal adenomas at 25 years
of age or older and/or a late onset of disease (≥45 years of age)
irrespective of polyp number.15
3.1.1 Can a diagnosis be made other than through a genetic test?








Other (please describe): In case of sporadic cases or AFAP, differentiating
FAP, MUTYH-associated polyposis (MAP),16 and
polymerase proofreading-associated
polyposis (PPAP)17 can be achieved by molecular
genetic analysis only.
Comment:
The most relevant differential diagnoses of an attenuated/late-onset
FAP is the autosomal recessive MAP caused by biallelic MUTYH
germline mutations (see CUGC MAP16) and the autosomal dominant
PPAP caused by specific heterozygous POLE or POLD1 germline
missense mutations.17
In case of a low number of (synchronous) adenomas, Lynch
syndrome (previously referred to as hereditary non-polyposis color-
ectal cancer) (see CUGC Lynch syndrome18) should be considered.
3.1.2 Describe the burden of alternative diagnostic methods to the
patient. The diagnosis colorectal polyposis in a clinically affected
person can only be established by colonoscopy and subsequent
histological examination of removed polyps, which is a burdensome
examination. Alternative burdenless diagnostic methods are ocular
fundus examination and mandibular radiography, but these methods
are helpful in only a few patients.
3.1.3 How is the cost effectiveness of alternative diagnostic methods to
be judged?
• Very cost effective and time saving but not useful for predictive testing.




Therapy (please describe) In general, the management of FAP is based on
the clinical course of the disease and not on the
results of mutation screening. However, in some
cases, the position of the mutation might be
considered for the type and time of colorectal





If the position of the mutation supports the
clinical diagnosis of an attenuated disease, it
affects the protocol of endoscopic surveillance
(age at beginning, colonoscopy instead of sig-
moidoscopy in AFAP).20
3.2 Predictive Setting: The tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if in 1.9 ‘B’ was marked)
3.2.1 Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe)
• Yes: Increase in compliance to participate in specific preventive
surveillance programs (in particular colonoscopy and upper gastro-
intestinal endoscopy). In some cases, the position of the mutation
might affect the procedure and time of surgical management
(although the decision of colectomy should be based mainly on
the clinical phenotype).
• In some cases, family planning, choice of profession.
If the test result is negative (please describe).
• Yes. Release from intensified screening program. Psychological relief.
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3.2.2 Which options in view of lifestyle and prevention does a person
at-risk have if no genetic test has been done (please describe)?
• Same as for proven mutation carriers: Close-meshed early diagnosis
and surveillance programs, colectomy when numerous polyps have
been detected. Yet, these measures are taken in vain in half of the
persons at risk (non-carriers).
3.3 Genetic risk assessment in family members of a diseased person
(To be answered if in 1.9 ‘C’ was marked)
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
• Yes (if the mutation is known in the family).
3.3.2 Can a genetic test in the index patient save genetic or other tests
in family members? Yes:
• By securing the primary cause of the disease, extended diagnostic
investigations in other symptomatic relatives can be avoided.
• By exclusion of a carrier status in predictive diagnostics, superfluous
preventive investigations can be avoided and psychological relief is
obtained.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
• Yes.
3.4 Prenatal diagnosis
(To be answered if in 1.9 ‘D’ was marked).
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
• Technically yes, after considering specific rules and ethical aspects.
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
nevertheless useful for the patient or his/her relatives? (Please describe)
• Support for family life organization.
• Efficiency of subsequent clinical management.
• For many patients, proof of diagnosis is a value itself – irrespective
of a medical benefit – because the disease and its cause can clearly
be named.
• When a genetic cause is verified, an assumption of ‘own fault’ as
cause of disease (exogenous poisons, ‘wrong conduct’) often can be
lapsed with relief.
• The main benefits of genetic diagnostics in FAP are the differentia-
tion from MAP (which, for example, do not have a risk for
developing desmoid tumours), a precise recurrence risk calculation
for close relatives, and relief of non-carriers during predictive
testing, and a tailored surveillance program including prophylactic
surgery options.20
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This work was supported by EuroGentest2 (Unit 2: ‘Genetic testing as part of
health care’), a Coordination Action under FP7 (Grant Agreement Number
261469) and the European Society of Human Genetics, by the German Cancer
Aid (Deutsche Krebshilfe e.V.; Grant Number 108421), and by the French
National Cancer Institute (InCA Grant 2004-11).
1 Lagarde A, Rouleau E, Ferrari A et al: Germline APC mutation spectrum derived from
863 genomic variations identified through a 15-years medical genetics service to
French FAP patients. J Med Genet 2010; 47: 721–722.
2 Friedl W, Aretz S. Familial Adenomatous Polyposis: Experience from a Study of 1164
Unrelated German Polyposis Patients. Hered Cancer Clin Pract 2005; 3: 95–114.
3 Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis
(FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994; 3: 121–125.
4 Aretz S, Uhlhaas S, Caspari R et al: Frequency and parental origin of de novo APC
mutations in familial adenomatous Polyposis. Eur J Hum Genet 2004; 12: 52–58.
5 Aretz S, Stienen D, Uhlhaas S et al. Large submicroscopic genomic APC deletions are a
common cause of typical familial adenomatous polyposis. J Med Genet 2005; 42:
185–192.
6 Michils G, Tejpar S, Thoelen R et al. Large deletions of the APC gene in 15% of
mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat
2005; 25: 125–134.
7 Spier I, Horpaopan S, Vogt S et al. Deep intronic APC mutations explain a substantial
proportion of patients with familial or early-onset adenomatous polyposis. Hum Mutat
2012; 33: 1045–1050.
8 Aretz S, Stienen D, Friedrichs N et al: Somatic APC mosaicism: a frequent cause of
familial adenomatous polyposis (FAP). Hum Mutat 2007; 28: 985–992.
9 Jasperson KW, Burt RW: APC-Associated polyposis conditions, 18 December 1998
(updated 27 March 2004). In: Pagon RA, Adam MP, Ardinger HH et al: (eds).
GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, 1993-2014.
Available at www.ncbi.nlm.nih.gov/books/NBK1345/.
10 Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A. Working Group of the American
College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance
Committee.; ACMG technical standards and guidelines for genetic testing for
inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and
MYH-associated polyposis). Genet Med 2014; 16: 101–116.
11 Bülow S, Faurschou Nielsen T, Bülow C, Bisgaard ML, Karlsen L, Moesgaard F.
The incidence rate of familial adenomatous polyposis. Results from the Danish
Polyposis Register. Int J Colorectal Dis 1996; 11: 88–91.
12 Bülow S. Results of national registration of familial adenomatous polyposis. Gut 2003;
52: 742–746.
13 Douma KF, Aaronson NK, Vasen HF, Verhoef S, Gundy CM, Bleiker EM. Attitudes
toward genetic testing in childhood and reproductive decision-making for familial
adenomatous polyposis. Eur J Hum Genet 2010; 18: 186–193.
14 Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;
101: 385–398.
15 Knudsen AL, Bülow S, Tomlinson I, Möslein G, Heinimann K, Christensen IJ.
Attenuated familial adenomatous polyposis: results from an international
collaborative study. Colorectal Dis 2010; 12: e243–e249.
16 Aretz S, Genuardi M, Hes FJ. Clinical utility gene card for: MUTYH-associated polyposis
(MAP), Autosomal recessive colorectal adenomatous polyposis, Multiple colorectal
adenomas, Multiple adenomatous polyps (MAP) - update 2012. Eur J Hum Genet
2013; 21: doi:10.1038/ejhg.2012.163.
17 Palles C, Cazier JB, Howarth KM et al: Germline mutations affecting the proofreading
domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
Nat Genet 2013; 45: 136–144.
18 Rahner N, Steinke V, Schlegelberger B, Eisinger F, Hutter P, Olschwang S. Clinical
utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update
2012. Eur J Hum Genet 2013; 21: doi:10.1038/ejhg.2012.164.
19 Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype
of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol
Hematol 2007; 61: 153–161.
20 Vasen HFA, Möslein G, Alonso A et al: Guidelines for the clinical management of
familial adenomatous polyposis (FAP). Gut 2008; 57: 704–713.
Clinical Utility Gene Card update
S Aretz et al
e4
European Journal of Human Genetics
